The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas.
暂无分享,去创建一个
[1] David T. W. Jones,et al. Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1 , 2019, Acta Neuropathologica.
[2] David T. W. Jones,et al. Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA , 2019, Acta Neuropathologica.
[3] Sarah E. Dorff,et al. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation , 2019, Clinical Cancer Research.
[4] B. Tuch,et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] D. Sinnett,et al. Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma , 2018, Oncogene.
[6] David T. W. Jones,et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis , 2018, Brain pathology.
[7] David T. W. Jones,et al. Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas , 2018, Acta Neuropathologica.
[8] D. Sinnett,et al. Trametinib for progressive pediatric low-grade gliomas , 2018, Journal of Neuro-Oncology.
[9] David T. W. Jones,et al. Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile , 2018, Acta Neuropathologica.
[10] David T. W. Jones,et al. FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma , 2018, Acta Neuropathologica.
[11] B. Radotra,et al. Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation. , 2018, Human pathology.
[12] N. André,et al. Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma. , 2018 .
[13] David T. W. Jones,et al. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features , 2018, Acta Neuropathologica.
[14] David T. W. Jones,et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations , 2018, Acta Neuropathologica.
[15] Michael C. Heinold,et al. The landscape of genomic alterations across childhood cancers , 2018, Nature.
[16] David T. W. Jones,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[17] Matthew Meyerson,et al. Landscapes of childhood tumours , 2018, Nature.
[18] D. Brat,et al. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle , 2018, Nature Communications.
[19] P. Varlet,et al. Co‐occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma , 2018, Brain pathology.
[20] Raquel S. Sevilla,et al. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit , 2017, Scientific Reports.
[21] D. Gutmann,et al. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. , 2017, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[22] M. Prados,et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.
[23] K. Ligon,et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Roland Eils,et al. The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.
[25] K. Davies,et al. Desmoplastic infantile astrocytoma/ganglioglioma with rare BRAF V600D mutation , 2017, Pediatric blood & cancer.
[26] D. Ellison,et al. Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination , 2017, Acta Neuropathologica.
[27] J. Majewski,et al. Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma , 2017, Pediatric Blood & Cancer.
[28] A. Unterberg,et al. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo , 2017, Acta Neuropathologica.
[29] K. Ligon,et al. Pediatric low-grade gliomas: implications of the biologic era , 2016, Neuro-oncology.
[30] Uri Tabori,et al. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma , 2016, Acta Neuropathologica Communications.
[31] David T. W. Jones,et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking , 2016, Neuro-oncology.
[32] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[33] Mark L. Greenberg,et al. Clinical and treatment factors determining long‐term outcomes for adult survivors of childhood low‐grade glioma: A population‐based study , 2016, Cancer.
[34] David T. W. Jones,et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors , 2016, Acta Neuropathologica.
[35] Heather L. Mulder,et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology , 2016, Acta Neuropathologica.
[36] Liliana Goumnerova,et al. MYB-QKI rearrangements in Angiocentric Glioma drive tumorigenicity through a tripartite mechanism , 2016, Nature Genetics.
[37] David T. W. Jones,et al. Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age , 2015, Oncotarget.
[38] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[39] Alexander R. Pico,et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.
[40] Gary D Bader,et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.
[41] Satoru Miyano,et al. Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.
[42] P. Varlet,et al. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours , 2015, Neuropathology and applied neurobiology.
[43] D. Merico,et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Meixensberger,et al. Disseminated oligodendroglial cell-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity , 2015, Journal of Neuro-Oncology.
[45] O. Witt,et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. , 2014, The Lancet. Oncology.
[46] J. Majewski,et al. Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors , 2014, Acta Neuropathologica.
[47] T. Pietsch,et al. FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle. , 2014, Journal of neuropathology and experimental neurology.
[48] Liliana Goumnerova,et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma , 2014, Nature Genetics.
[49] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[50] J. Golfinos,et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. , 2014, Neuro-oncology.
[51] R. Beroukhim,et al. Long-Term Outcome of 4,040 Children Diagnosed With Pediatric Low-Grade Gliomas: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database , 2014, Pediatric blood & cancer.
[52] David T. W. Jones,et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge , 2014, Nature Reviews Cancer.
[53] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[54] A. Fontebasso,et al. Molecular biomarkers in pediatric glial tumors: a needed wind of change , 2013, Current opinion in oncology.
[55] K. Blomgren,et al. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species , 2013, Progress in Neurobiology.
[56] Roland Eils,et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.
[57] Liliana Goumnerova,et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1 , 2013, Proceedings of the National Academy of Sciences.
[58] C. Stewart‐Amidei,et al. A new reality: long-term survivorship with a malignant brain tumor. , 2013, Oncology nursing forum.
[59] A. Resnick,et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas , 2013, Proceedings of the National Academy of Sciences.
[60] M. Rosenblum,et al. Identification of a Novel, Recurrent SLC44A1‐PRKCA Fusion in Papillary Glioneuronal Tumor , 2013, Brain pathology.
[61] N. Foreman,et al. Brainstem ganglioglioma successfully treated with vemurafenib. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] E. Thiele,et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.
[63] W. Snider,et al. MEK Is a Key Regulator of Gliogenesis in the Developing Brain , 2012, Neuron.
[64] D. Brat,et al. Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.
[65] M. Rosenblum,et al. Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity , 2012, Acta Neuropathologica.
[66] Andrey Korshunov,et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.
[67] R. McLendon,et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.
[68] K. Aldape,et al. Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor , 2012, Acta Neuropathologica.
[69] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[70] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[71] Zhaoshi Jiang,et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] S. Pfister,et al. Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas , 2011, Clinical Cancer Research.
[73] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[74] D. Frappaz,et al. Brain tumors: from childhood through adolescence into adulthood. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] S. Shurtleff,et al. MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas , 2010, Acta Neuropathologica.
[76] M. J. van den Bent. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta neuropathologica.
[77] M. Fassan,et al. Diffuse Leptomeningeal Glioneuronal Tumors: A New Entity? , 2010, Brain pathology.
[78] D. Wilkinson,et al. Neuronal regulation of the spatial patterning of neurogenesis. , 2010, Developmental cell.
[79] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[80] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[81] D. Desruisseau,et al. Pilocytic astrocytoma in a child with Noonan syndrome , 2009, Pediatric blood & cancer.
[82] A. Montpetit,et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours , 2009, British Journal of Cancer.
[83] D. Pearson,et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma , 2009, Oncogene.
[84] B. Scheithauer,et al. ROSETTE‐FORMING GLIONEURONAL TUMOR: REPORT OF A CHIASMAL‐OPTIC NERVE EXAMPLE IN NEUROFIBROMATOSIS TYPE 1 SPECIAL PATHOLOGY REPORT , 2009, Neurosurgery.
[85] David T. W. Jones,et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.
[86] E. Kanavakis,et al. Tumor development in three patients with Noonan syndrome , 2008, European Journal of Pediatrics.
[87] G. Reifenberger,et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.
[88] A. Hoischen,et al. Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas , 2007, Oncogene.
[89] David T. W. Jones,et al. Genomic Analysis of Pilocytic Astrocytomas at 0.97 Mb Resolution Shows an Increasing Tendency Toward Chromosomal Copy Number Change With Age , 2006, Journal of neuropathology and experimental neurology.
[90] I. Pollack,et al. Pediatric brain tumors. , 1999, Seminars in surgical oncology.
[91] R. Sanford,et al. A 16-Year-Old Male with Noonan’s Syndrome Develops Progressive Scoliosis and Deteriorating Gait , 1999, Pediatric Neurosurgery.
[92] B. Brody,et al. Sequence of Central Nervous System Myelination in Human Infancy. I. An Autopsy Study of Myelination , 1987, Journal of neuropathology and experimental neurology.
[93] David T. W. Jones,et al. BRAF V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] J. Huse,et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) , 2017 .
[95] David T. W. Jones,et al. New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[96] A. Fontebasso,et al. Pediatric Brain Tumors: Genomics and Epigenomics Pave the Way. , 2015, Critical reviews in oncogenesis.
[97] Jill S. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.
[98] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[99] Frank M. Sacks,et al. IDH 1 and IDH 2 Mutations in Gliomas , 2009 .
[100] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[101] U. Roessmann,et al. Astrocytes in the developing human brain. An immunohistochemical study. , 1986, Acta neuropathologica.